U.S. FDA approves Mirati’s lung cancer drug

(Reuters) – The U.S. Food and Drug Administration on Monday approved Mirati Therapeutics Inc’s lung cancer drug adagrasib, according to the health regulator’s website.

(Reporting by Raghav Mahobe in Bengaluru; Editing by Shounak Dasgupta)